key: cord-0686757-4zk473c1 authors: Mehta, Piyush P.; Dhapte-Pawar, Vividha S. title: Novel and Evolving Therapies for COVID-19 Related Pulmonary Complications date: 2021-02-25 journal: Am J Med Sci DOI: 10.1016/j.amjms.2021.02.019 sha: c900bbf83f9325976d902b175068845dc5e2d9b9 doc_id: 686757 cord_uid: 4zk473c1 Coronaviruses disease 2019 (COVID-19) is the most crucial threat, the world has ever witnessed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of this disease pandemic. The World Health Organization has confirmed the continuing epidemic as a worldwide public health crisis. Presently, the research on COVID-19 is even in the primitive stage. Studies on unveiling the natural route of COVID-19 infection and related pathophysiology, the biology of pulmonary airways pose a more rational restorative approach in the management of COVID-19. Thus, based on the existing facts, we methodically reviewed the efforts put forth by various research institutes, pharmaceutical companies and biotechnology firms in pulmonary delivery to prevent and control the COVID-19. This article would be valuable for the healthcare community, which is efficiently dealing with the SARS-CoV-2 crisis. Once again, the human race is experiencing a global viral pandemic of a zoonotic basis. In December 2019, the novel coronavirus (COVID- 19) infecting humans was primarily recognized in Wuhan, China. 1 The National Health Commission of China had reported thousands of COVID-19 positive cases with subsequent COVID-19 victims confirmed worldwide. 2 As of May 9, 3.94 million verified cases of COVID-19 and 2,75,429 fatalities had been reported in 209 nations and territories. Coronaviruses are RNA viruses that are genotypically and phenotypically diverse. 2 Besides, in human beings, coronaviruses are prevalent in other species such as monkeys, birds, cats, dogs, rabbits, pigs, reptiles and bats. 2 They can instigate respiratory, neurological, hepatic and enteric diseases of erratic severity, which may be fatal to human beings. 2 Two of the earlier recognized strains of coronavirus i.e. severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have led to this prevalence of this pandemic which is zoonotic in origin. 1, 2 On February 10 (2020), the World Health Organization (WHO) termed a new virus as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The rapid spread of person-to-person transmission of SARS-CoV-2 has now been recognized. 3 Vigorous efforts and investments are made by the individual nations by closing the transportation systems, quarantining whole cities, imposing the use of personal preventive equipment (PPEs) such as face masks and establishing better personal sanitation practice to control the transmission of COVID-19. 4, 5 The situation with SARS-CoV-2 is growing exponentially with the numbers of COVID-19 positive cases growing into the thousands. 6 Now, it is apparent that the COVID-19 may turn into an endemic ground of viral pneumonia. 7 Accelerating the development of useful and safe therapeutic options against COVID-19 is the world's top priority to rescue the lives during the pandemic. The best hope for the prevention or control of COVID-19 is a vaccine. However, no prophylactic (vaccine) option exists to prevent COVID-19 infection. Thus, currently, various health agencies across the globe are actively collaborating with many research institutes, biotechnology, pharmaceutical and medicine product developers for the advancement in effective medicines against COVID-19. Additionally, few dynamic investigators are working on different treatment options such as the codonoptimized MERS-S1 subunit vaccines loaded microneedle arrays 8 , monoclonal antibodies (e.g. tocilizumab; recombinant humanized monoclonal antibody) for passive immunotherapy 8,9 , drug repurposing (e.g. lopinavir, remdesivir, favipiravir, ivermectin, hydroxy-chloroquine, baricitinib and camostat) 10, 11 alternative to fight against the COVID-19. Moreover, the virusdirected therapies such as viral entry inhibitors (e.g. chloroquine), viral fusion inhibitors (e.g. griffithsin), viral helicase inhibitors (e.g. bananins) and viral protease inhibitors (e.g. cinanserin) are also well studied and tested by few active research groups. 12 Further, by understanding the present community needs, few dynamic material engineers fabricated nanoparticle-based superfine filters 13 , surfaces coating agents 13 and reusable silicon-based hydrophobic nanoporous (< 5 nm) anti-COVID face-masks 14 to resist the direct viral contact and transmission. Besides, researchers from Hue University have recently investigated the essential oil from Garlic (Allium sativum L.) against COVID-19 in molecular docking studies. 15 The docking results showed that the organosulfur compounds (e.g. allyl disulfide and allyl trisulfide) effectively inhibit the angiotensin-converting enzyme 2 (ACE2; membrane glycoprotein of the host) and attacking the PDB6LU7 protein, the main protease of SARS-CoV-2. This inhibitory action regulates the PDB6LU7 protein maturation of the COVID-19 and the further spread of infection. 15 Another appealing alternative for exploration is to exercise the pulmonary drug delivery system to prevent or control the COVID-19 infection. The site of primary infection (upper respiratory tract and central pulmonary airways via direct surface contact or deposition of inhaled droplets), the way of COVID-19 progression and biology of pulmonary airways represent a more logical remedial tactic for the management of COVID-19. 16, 17 Therefore, therapeutics that target the pulmonary airways and generate airways-resident immunity may be principally beneficial for preventing or controlling COVID-19 infection. 18 Based on this concept, the present article summarizes various active efforts put forth by various pharmaceutical organizations, biological multinationals and research institutes to prevent or control the COVID-19 infection via the orally inhaled and nasal drug products (OINDPs) systems. Finally, it also highlights the future aspects of inhalation treatment for COVID-19 infection. The OINDPs such as pressurized metered-dose inhalers (MDIs), dry powder inhalers (DPIs), soft mist inhalers (SMIs) and nebulizing systems are the four most commonly used pulmonary drug delivery systems. 19 Vaccine delivery using the OINDPs approach has been well suggested for improving the systemic and mucosal immunity to airborne viruses such as influenza, measles, cytomegalovirus and papilloma virus. 20 Additionally, the marketed products such as FluenzTetra TM (Respiratory vaccine, EU), Flumist ® (MedImmune, USA), Fluenz ® (Astra Zeneca, EU) and Nasovac ® (Serum Institute of India, India) have influenced the management of viral diseases prominently, which greatly benefited mankind. 20 Accordingly, several dynamic scientists and researchers have invested similar dynamic efforts to prevent and control the COVID-19. The summary of all active efforts taken by dynamic researcher and clinicians for the clinical development of COVID-19 vaccine are described in Table 1 . The vaccine companies FluGen (US) and Bharat Biotech (India) in partnership with the University of Wisconsin-Madison (US) have initiated the development and testing of a unique intranasal vaccine (CoroFlu) against SARS-CoV-2 for the preclusion of COVID-19. The CoroFlu vaccine will be an adaptation of Madison-based FluGen's intranasal flu vaccine (M2SR). 21 Very recently, phase 2 trial of M2SR showed that the intranasal vaccine defends against the highly mismatched influenza strain. Thus, to formulate a vaccine against COVID-19, gene sequences from SARS-CoV-2 will be affixed into M2SR. Specifically, the spike protein that the coronavirus uses to adhere onto human cells and initiate infection will be pinned into M2SR. The Kawaoka group (University of Wisconsin-Madison) will affix the genetic sequences from SARS-CoV-2 into whereas Ethris is working on the use of a unique pulmonary therapeutics platform to deliver the same. 22 The proposed antibody therapy will be based on Ethris' stabilized nonimmunogenic mRNA (SNIM ® RNA) technology. The Ethris' pulmonary SNIM ® RNA technology would assist in the administration of mRNA-encoded, neutralizing anti-SARS-CoV-2 antibodies directly in patients' lungs for rapid attainment of effective pulmonary antibody concentrations. Briefly, this state-of-the-art pulmonary technology offers the prospects to treat the viral lung disease that is the primary driver of morbidity and mortality. 22 These collaborative firms aspire for rapid development of this novel treatment to curb this pandemic effectively. APEPTICO is well-known Austria-based biotechnology company actively developing peptidebased medicinal products for several life-threatening pulmonary disorders such as severe respiratory failure, acute respiratory distress syndrome (ARDS) and pulmonary oedema. APEPTICO's key candidate, solnatide is purposefully developed for the management of lifethreatening acute pulmonary dysfunction and pulmonary oedema in ARDS subjects. Solnatide is a water-soluble synthetic peptide. It is a resemblance with the lectin-like domain of human Tumour Necrosis Factor-alpha (TNF alpha). Solnatide mainly activates the pulmonary epithelial sodium channel and restores the injured endothelial-epithelial barrier of pulmonary alveoli. 23, 24 In 2013, APEPTICO fruitfully concluded phase 1 clinical study in healthy subjects, verifying the safety of solnatide. Additionally, APEPTICO also effectively finished a randomized, double- Nitric oxide (NO) is an essential endogenous substance obtained from arginine in mammalian cells via three key enzymes i.e. neuronal, endothelial and inducible nitric oxide synthase (iNOS). 28 NO is an important element of the lungs and it plays a vital physiological role in the management of pulmonary vasomotor tone. 29 It increases the levels of cyclic guanosine monophosphate and regulate the pulmonary smooth muscle tone. 29 Additionally, it retains the standard vascular function and control inflammatory progression in the state of moribund endothelial function. 28 Particularly, the inhaled NO therapy is commonly prescribed in the persistent pulmonary hypertension of the newborn (PPHN), acute lung injury and ARDS. 30 The iNOS functioning is normally raised during viral infection (e.g. SARS-CoV-1 infection) and NO hinders the viral replication through a cytotoxic reactions via intermediate, peroxynitrite. 28, 31 However, the SARS-CoV-2 infects endothelial cells, which are a key resource of NO synthesis. 28 Therefore, in SARS-CoV-2 management, inhaled NO may be helpful to restore endothelial function and control inflammatory responses. Therefore, two inhaled NO delivery systems i.e. VERO's GeNOsyl ® iNO system and Beyond Air LungFit™ platform are discussed below. Vero Biotech LLC (Georgia) is a biotechnology corporation focused on the design and development of products to tackle the medical needs of patients suffering from pulmonary diseases. VERO Biotech LLC developed next-generation inhaled NO delivery systems. GeNOsyl ® Acute DS and lightweight portable GeNOsyl ® Chronic DS are designed for use in the hospital and outside the hospital settings, respectively. 30, 32 In December 2019, US FDA approved GeNOsyl ® iNO system for the treatment of PPHN. The single-use ventilator and nasal cannula or mask are supplied with the GeNOsyl ® Acute DS and GeNOsyl ® Chronic DS to deliver the NO, respectively. Additionally, the disposable drug cassette is also available to ease the treatment function. Ultimately, the VERO's GeNOsyl ® iNO system is helpful in the COVID-19 emergency with shortage of ventilators at medical centers. A handy, disposable GeNOsyl ® iNO system in either the medical center or residence enables healthcare practitioners the flexibility to serve patients with inhaled NO effectively. 32 Beyond Air is a US-based biopharmaceutical company actively working on inhaled NO products for several life-threatening pulmonary disorders. Beyond Air's lead platform system, LungFit™ is specially designed to generate and deliver NO from ambient air. Beyond Air already possess the LungFit™ PH and LungFit™ BRO devices to deliver NO dosage to the pulmonary airways for a patient suffering from PPHN and non-tuberculous mycobacteria, respectively. In this prevailing pandemic situation, Beyond Air submitted an investigational device exemption (IDE) to the USFDA for using its cylinder-free LungFit™ BRO inhaled NO delivery system in the treatment of COVID-19. 33 Windtree Therapeutics Inc. is a US-based biotechnology firm dynamically working on developing KL4 surfactant therapies for critical pulmonary airway diseases. KL4 surfactant therapy is a life-saving remedy for respiratory distress syndrome (RDS). 34 The UK biotech, Synairgen, is a drug discovery and development company established by the Synairgen is actively designing a formulation of Interferon-beta (IFN-beta), named SNG001 for direct, pulmonary delivery via nebulization for therapy and/or prophylaxis of lower respiratory tract diseases caused by respiratory viruses. IFN-beta is a natural protein, which coordinates the human's antiviral responses. The deficiency of IFN-beta in pulmonary airways may enhance the vulnerability to develop severe lung disease during respiratory viral infections. 40 anti-inflammatory approach to effectively control the hyper-inflammation in hospitalized COVID-19 subjects prone to acute lung injury and ARDS. 48 As well, pre-clinical studies showed that TD-0903 has a high lung: plasma ratio and quick metabolic clearance ensuing in low systemic exposure and delivery route (nebulizer), which improves its pulmonary airway selectivity. Moreover, pre-clinical pharmacodynamic trials exhibited that TD-0903 has an extensive period of action, which allows once or twice daily dosing in subjects. Therefore, Theravance Biopharma submitted the clinical trial application to regulatory authorities to initiate clinical progress of TD-0903 for impediment of cytokine storm in hospitalized COVID-19 patients. After Clinical Trial Application approval, Theravance Biopharma will rapidly start Phase 1 single and multiple ascending dose study in UK with 2-part Phase 2 study in hospitalized COVID-19 patients. 47 Marinomed Biotech (Austria) is a well-known biopharmaceutical corporation that develops novel systems to treat various pulmonary diseases. Marinomed is mainly working on the polymer Carragelose ® . Carragelose ® is a distinctive, broadly active anti-viral molecule for treating various pulmonary conditions. It is a sulfated polymer obtained from red seaweed algae, approved for marketing in EU, Australia and parts of Asia as component of throat sprays, nasal sprays and lozenges. As per Marinomed, a study performed in 2014 showed that treatment with Carragelose ® decreased the period of symptoms by 3 days in patients infected with a coronavirus compared to placebo. 49 Carragelose ® forms a protective physical barrier on the oral and nasal mucosa, thereby avoiding entry and/or binding of the pulmonary viruses into the cells (Fig. 1) . 50 Ciclesonide, a glucocorticoid normally prescribed for asthma is sold under the brand name Alvesco (Covis Pharma, Luxembourg). Alvesco pressurized meter dose inhaler (80 to 320 µg ciclesonide/actuation) is used for maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients of 12 years and older age in US. In COVID-19 subjects, the ciclesonide is anticipated to reduce signs and restrain the viral replication. Thus, recently, USFDA has approved an IND application for a Phase 3 clinical study to assess Alvesco pandemic has shaped uncertainty, fear and anxiety about wellbeing and life that have challenged mental health, globally. To manage anxiety-related disorders, the safe and novel fast-acting treatment options are needed. Therefore, to address the current mental health challenges, VistaGen Therapeutics, Inc. emerged with the PH94B neuroactive nasal spray. The PH94B is a novel, odorless, rapid-onset nasal drug delivery system. PH94B specifically binds to nasal chemosensory receptors and trigger neural circuits in the brain that suppress anxiety and fear allied with everyday social conditions and other routine situations. Additionally, VistaGen Therapeutics, Inc. completed Phase 2 (NCT01217788) 59 and Phase 3 (NCT02622958) 60 clinical trials effectively. Also, they proved thePH94B nasal spray (8 µg spray) efficacy in acute treatment of social anxiety disorders. Following these clinical trials, VistaGen Therapeutics, Inc., should utilize PPEs and take great concern during routine practice to strengthen the battle against the present adverse zoonotic spillover. Challenges of corona virus disease 2019 Game consumption and the 2019 novel corona virus SARS-CoV-2 and COVID-19: The most important research questions World Health Organization declares global emergency: A review of the 2019 novel corona virus (COVID-19) COVID-19: A Call for Physical Scientists and Engineers Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing Features, evaluation and treatment corona virus (COVID-19) Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development Effective treatment of severe COVID-19 patients with tocilizumab Potential therapeutic agents against COVID-19: What we know so far Quest for a COVID-19 Cure by Repurposing Small-Molecule Drugs: Mechanism of Action, Clinical Development, Synthesis at Scale, and Outlook for Supply Current Perspective of Antiviral Strategies against COVID-19 Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic Flexible Nanoporous Template for the Design and Development of Reusable Anti-COVID-19 Hydrophobic Face Masks Investigation into SARS-CoV-2 resistance of compounds in garlic essential oil Urgent Appeal from International Society for Aerosols in Medicine (ISAM) During COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group Hypothesis: Nasal vs. oral inhalation accounts for the severity of COVID Corona virus infections: Epidemiological, clinical and immunological features and hypotheses Recent advances in inhalable liposomes for treatment of pulmonary diseases: Concept to clinical stance Mucosal Vaccination via the Respiratory Tract FluGen, Bharat Biotech to develop CoroFlu Neurimmune and ethris sign collaboration agreement to rapidly develop inhaled mrna-based antibody therapy for the treatment of COVID-19 TnF lectin-like Domain restores epithelial sodium channel Function in Frameshift Mutants associated with Pseudo hypoaldosteronism Type 1B Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebocontrolled trial Solnatide has been approved by the Austrian Federal Office for Safety in Health Care (BASG) for the treatment of COVID-19 patients with severe pulmonary dysfunction Altimmune Completes First Development Milestone Toward A Single-Dose Intranasal COVID-19 Vaccine Single-Dose intranasal COVID-19 Vaccine Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19 Nitric oxide in the lung: therapeutic and cellular mechanisms of action Innovation in inhaled nitric oxide delivery Inhaled nitric oxide therapy fails to improve outcome in experimental severe influenza Georgia, 2020a. Innovation. Vero Biotech Beyond Air Inc., US, 2020. Beyond Air Accelerates LungFit™ BRO COVID-19 Program Aerosurf ® (lucinactant for inhalation) aerosolized KL4 surfactant Early CPAP versus surfactant in extremely preterm infants Nasal CPAP or intubation at birth for very preterm infants Trial to assess the safety and tolerability of lucinactant for inhalation in premature neonates Windtree Therapeutics to study its KL4 surfactant for COVID-19 INF-β for treatment of COVID-19 Identifier: NCT01126177. Comparing efficacy and safety of inhaled SNG001 to placebo Identifier: NCT03570359. A study to test a potential new treatment for copd patients suffering from the common cold or influenza Infection prevention and control of epidemic-and pandemic-prone acute respiratory infections in health care. Geneva: World Health Organization POCUS in COVID-19: pearls and pitfalls Dry powder inhalers: a concise summary of the electronic monitoring devices Current and Perspective Diagnostic Techniques for COVID Destiny Pharma and SporeGen® announce collaboration and Innovate UK grant award to co-develop novel Diomics Aims to Nose Out Coronavirus Ahead of Vaccines With Nasal Spray That Delivers Monoclonal Antibody Protection Partner Therapeutics, US, 2020. Partner Therapeutics Initiates Patient Enrollment in Clinical Trial Evaluating Leukine® (rhuGM-CSF, sargramostim) in COVID-19 Patients FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure Atossa to advance AT-301 nasal spray into clinical development for COVID-19 CEBINA identifies a common antihistamine nasal spray as a potential anti-COVID-19 approach Meissa Vaccines Provides a Pipeline Update on Vaccine Candidatesfor COVID-19 and RSV Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody for Clinical Studies in Patients with COVID-19 Figure Legend Figure 1: Carragelose ® physically interacts with mucosal surfaces and creates a protective physical barrier to prevent binding and/or entry of the respiratory viruses into the cells Authors are thankful to Bharati Vidyapeeth University, Poona College of Pharmacy, Pune-38, India for support and institutional facilities. This article did not get any specialized funding from funding agencies in the community, business, or not-for-profit segments. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.